XL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
More Information Supplier PageXL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
More Information Supplier PageXL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
More Information Supplier PageBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
More Information Supplier PageBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
More Information Supplier PageSB 415286 is a potent and selective cell-permeable, ATP-competitive inhibitor of GSK3?? with an IC50 value of 78 nM (similar potency for GSK3??) and a Ki value of 31 nM.
More Information Supplier PageSB 415286 is a potent and selective cell-permeable, ATP-competitive inhibitor of GSK3?? with an IC50 value of 78 nM (similar potency for GSK3??) and a Ki value of 31 nM.
More Information Supplier PageSB 415286 is a potent and selective cell-permeable, ATP-competitive inhibitor of GSK3?? with an IC50 value of 78 nM (similar potency for GSK3??) and a Ki value of 31 nM.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier Page
